Efficacy News and Research

RSS

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)

30 Jun 2014

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Engineers and neuroscientists at Duke University have developed a method to measure the response of an individual neuron to transcranial magnetic stimulation (TMS) of the brain. The advance will help researchers understand the underlying physiological effects of TMS -- a procedure used to treat psychiatric disorders -- and optimize its use as a therapeutic treatment.

30 Jun 2014

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014.

28 Jun 2014

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

28 Jun 2014

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.

28 Jun 2014

Newly identified compound may halt progression of Alzheimer's disease

Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline.

28 Jun 2014

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex Disinfection Services, the world leader in UV room disinfection systems, testified yesterday before the U.S. House of Representatives Committee on Science, Space, and Technology; Subcommittee on Research and Technology; and Subcommittee on Oversight.

28 Jun 2014

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide.

28 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

First step toward new drugs that can transcend antibiotic resistance issues

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health.

28 Jun 2014

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.

27 Jun 2014

Researchers perform systematic review to identify best treatments for cancer-related depression

27 Jun 2014

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study.

27 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

26 Jun 2014

Efficacy News and Research

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Light-sensitive molecule enables noninvasive silencing of neurons

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

Newly identified compound may halt progression of Alzheimer's disease

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

First step toward new drugs that can transcend antibiotic resistance issues

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Researchers perform systematic review to identify best treatments for cancer-related depression

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News